Samantha Semenkow
Stock Analyst at Citigroup
(3.57)
# 832
Out of 5,154 analysts
72
Total ratings
48.33%
Success rate
7.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $38 → $46 | $27.47 | +67.46% | 2 | Mar 5, 2026 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $33 → $35 | $24.24 | +44.39% | 4 | Mar 3, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $12 → $14 | $5.22 | +168.20% | 7 | Feb 25, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $33 | $15.74 | +109.66% | 1 | Feb 17, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $26 → $35 | $28.78 | +21.61% | 4 | Feb 10, 2026 | |
| ARGX argenx SE | Maintains: Buy | $1,124 → $1,091 | $717.79 | +51.99% | 8 | Jan 8, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $17 → $15 | $14.34 | +1.12% | 2 | Dec 22, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $64 | $40.15 | +59.40% | 1 | Dec 17, 2025 | |
| WVE Wave Life Sciences | Maintains: Buy | $16 → $30 | $13.12 | +128.66% | 2 | Dec 9, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $60 → $100 | $57.73 | +73.22% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $102 | $70.70 | +44.27% | 1 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $93.52 | +45.42% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $14 | $9.92 | +41.13% | 2 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4.25 | $4.01 | +5.99% | 5 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $20.29 | -26.07% | 5 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $18.15 | -72.45% | 3 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $3.17 | +215.46% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.30 | +73.91% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.90 | +207.69% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $15 | $3.15 | +376.19% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $80 | $30.00 | +166.67% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $2.00 | +650.00% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $26.66 | +87.55% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $26.54 | +111.00% | 3 | Aug 9, 2023 |
Agios Pharmaceuticals
Mar 5, 2026
Maintains: Buy
Price Target: $38 → $46
Current: $27.47
Upside: +67.46%
Catalyst Pharmaceuticals
Mar 3, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $24.24
Upside: +44.39%
Larimar Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $5.22
Upside: +168.20%
Cullinan Therapeutics
Feb 17, 2026
Initiates: Buy
Price Target: $33
Current: $15.74
Upside: +109.66%
Roivant Sciences
Feb 10, 2026
Maintains: Buy
Price Target: $26 → $35
Current: $28.78
Upside: +21.61%
argenx SE
Jan 8, 2026
Maintains: Buy
Price Target: $1,124 → $1,091
Current: $717.79
Upside: +51.99%
Amicus Therapeutics
Dec 22, 2025
Downgrades: Neutral
Price Target: $17 → $15
Current: $14.34
Upside: +1.12%
Spyre Therapeutics
Dec 17, 2025
Initiates: Buy
Price Target: $64
Current: $40.15
Upside: +59.40%
Wave Life Sciences
Dec 9, 2025
Maintains: Buy
Price Target: $16 → $30
Current: $13.12
Upside: +128.66%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $60 → $100
Current: $57.73
Upside: +73.22%
Nov 26, 2025
Initiates: Buy
Price Target: $102
Current: $70.70
Upside: +44.27%
Nov 25, 2025
Initiates: Buy
Price Target: $136
Current: $93.52
Upside: +45.42%
Nov 13, 2025
Maintains: Buy
Price Target: $28 → $14
Current: $9.92
Upside: +41.13%
Nov 11, 2025
Maintains: Neutral
Price Target: $5 → $4.25
Current: $4.01
Upside: +5.99%
Oct 29, 2025
Maintains: Buy
Price Target: $10 → $15
Current: $20.29
Upside: -26.07%
Oct 29, 2025
Downgrades: Sell
Price Target: $5
Current: $18.15
Upside: -72.45%
Aug 14, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $3.17
Upside: +215.46%
May 15, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $2.30
Upside: +73.91%
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.90
Upside: +207.69%
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $3.15
Upside: +376.19%
Jun 3, 2024
Reinstates: Buy
Price Target: $80
Current: $30.00
Upside: +166.67%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.00
Upside: +650.00%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $26.66
Upside: +87.55%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $26.54
Upside: +111.00%